Heart failure & cardiomyopathies
Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Incident Heart Failure Risk
Authors' conclusion
Independent of demographics, traditional risk factors, NT-proBNP, and CRP levels, proteomics-based suPAR levels were significantly associated with incident all-cause, ischemic, and nonischemic HF risk.
Study context
- Population
- UK Biobank participants without heart failure (HF) or CAD at enrolment
- Participants
- 40,418 participants
- Exposure
- Proteomics-based soluble urokinase plasminogen activator receptor (suPAR) levels and incident HF
- Outcome
- Incident all-cause, ischemic and nonischemic HF
- Follow-up
- Median 13.7 (IQR: 1.5) years
Methodological detailsUK Biobank, competing-risk regression
- UK Biobank
- Competing-risk regression
Main finding
As reported in the abstract
Incident HF per 1-SD suPAR
suPAR per 1-SDSubdistribution hazard ratio (95% CI)
All-cause HF
1.37(1.29–1.46)
Ischemic HF
1.40(1.28–1.54)
Nonischemic HF
1.32(1.21–1.44)
Per 1-SD, as printed
- Incident HF events
- 1,428 (3.5%)
Observational data: associations, not effects.
Further findings
Explained variability of incident HF risk, suPAR added to base risk factor model
- R 2 with vs without suPAR
- 0.76 vs 0.73
- P
- P < 0.001
Original publication
Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Incident Heart Failure Risk. JACC Adv. Published 9 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →